<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Stenotrophomonas maltophilia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Stenotrophomonas maltophilia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Stenotrophomonas maltophilia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sarah S Lewis, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Aimee Zaas, MD, MHS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel J Sexton, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 13, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H47084643"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Stenotrophomonas </em>(<em>Xanthomonas</em>) <em>maltophilia</em> is a multidrug-resistant gram-negative bacillus that is an opportunistic pathogen [<a href="#rid1">1-4</a>], particularly among hospitalized patients. <em>S. maltophilia</em> infections have been associated with high morbidity and mortality in severely immunocompromised and debilitated individuals.</p><p>The clinical features and management of <em>S. maltophilia</em> infections are discussed here. The general approach to gram-negative bacillary bacteremia, catheter-associated bloodstream infections, and hospital-acquired pneumonia are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3149.html" rel="external">"Gram-negative bacillary bacteremia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3814.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Treatment"</a> and  <a class="medical medical_review" href="/z/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults"</a>.)</p><p class="headingAnchor" id="H47084650"><span class="h1">MICROBIOLOGY</span><span class="headingEndMark"> — </span><em>S. maltophilia</em> is a ubiquitous, aerobic, nonfermentative, gram-negative bacillus that is closely related to the <em>Pseudomonas</em> species [<a href="#rid5">5</a>].</p><p>The organism was first isolated in 1943 and, at the time, was named <em>Bacterium bookeri</em>. It was later classified within the genus <em>Pseudomonas</em>, then <em>Xanthomonas</em>, and then finally <em>Stenotrophomonas</em> in 1993 [<a href="#rid4">4,6,7</a>]. The name signifies "a unit feeding on few substrates," based on the Greek roots stenos (narrow), trophos (one who feeds), and monas (a unit). <em>Maltophilia</em> means "affinity for malt," based on the Greek roots maltum (malt) and philia (affinity).</p><p><em>S. maltophilia</em> is the only species of <em>Stenotrophomonas</em> known to infect humans; its closest genetic relatives are plant pathogens [<a href="#rid7">7,8</a>]. It is frequently isolated from soil, water, animals, plant matter, and hospital equipment [<a href="#rid4">4,9-21</a>].</p><p><em>S. maltophilia</em> has an inherent ability to adhere to foreign materials and form a biofilm, rendering protection from host defenses as well as antimicrobial agents [<a href="#rid18">18,19,22-26</a>]. Factors contributing to this behavior include its positively charged surface and fimbrial adhesions [<a href="#rid7">7,22-24,26-28</a>].</p><p>In addition, <em>S. maltophilia</em> has intrinsic or acquired resistance mechanisms to several antibiotic classes. Resistance to beta-lactams, carbapenems, and <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a> is conferred by two inducible beta-lactamases: a zinc-containing penicillinase (L1) and a cephalosporinase (L2) [<a href="#rid21">21,29-34</a>]. Aminoglycoside resistance occurs due to an acetyl-transferase mechanism as well as temperature-dependent changes in the outer membrane lipopolysaccharide (LPS) structure [<a href="#rid18">18,35-45</a>]. In addition, many strains of <em>S. maltophilia</em> possess efflux pumps, which confer further resistance to multiple antibacterial classes [<a href="#rid41">41,46-49</a>].</p><p>There are uncertainties regarding the optimal approach to in vitro susceptibility testing given discrepancies between results of various methods [<a href="#rid50">50-53</a>]. The United States Clinical and Laboratory Standards Institute (CLSI) has published minimal inhibitory concentration (MIC) breakpoints for <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a>, ticarcillin-clavulanic acid, <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>, <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">cefiderocol</a>, and <a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">chloramphenicol</a> [<a href="#rid18">18,51,54,55</a>]. There are no MIC interpretive criteria for <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> or <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">tigecycline</a>, although susceptibility to tigecycline is assumed using interpretive criteria for Enterobacteriaceae<em> </em>[<a href="#rid56">56</a>]. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) has only published breakpoint criteria for trimethoprim-sulfamethoxazole [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H47084657"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The reported incidence of <em>S. maltophilia</em> infections ranges from 7.1 to 37.7 cases per 10,000 discharges [<a href="#rid4">4,41,50,58</a>]. The incidence seems to be increasing as the population of patients at risk increases [<a href="#rid1">1,4,51,59-61</a>]. Specifically, the increased incidence is probably due to advances in the treatment of malignancy, increased use of invasive devices, and widespread use of broad-spectrum antibiotics.</p><p>Risk factors associated with <em>S. maltophilia</em> infection include admission to an intensive care unit (ICU), malignancy, cystic fibrosis, neutropenia, mechanical ventilation, central venous catheters, recent surgery, trauma, HIV infection, and previous therapy with broad-spectrum antibiotics [<a href="#rid1">1,2,4,20,21,50,59,60,62</a>]. <em>S. maltophilia</em> infections are typically hospital-acquired; even in community-acquired infections, most affected individuals have significant health care exposure or predisposing comorbidities (eg, prior trauma, an immunocompromising condition, indwelling devices) [<a href="#rid63">63</a>].</p><p>A number of outbreaks of <em>S. maltophilia</em> have been described involving adult ICU patients [<a href="#rid64">64-66</a>], hematologic malignancy and bone marrow transplant recipients [<a href="#rid67">67,68</a>], hemodialysis patients [<a href="#rid69">69</a>], and neonates [<a href="#rid70">70,71</a>]. Patient exposure to contaminated tap water, ice machines, or soap has been the suspected etiology in many outbreaks [<a href="#rid66">66,68,70,72</a>]. In addition, a number of outbreaks and pseudo-outbreaks have been associated with failures in endoscope reprocessing [<a href="#rid73">73-79</a>].</p><p class="headingAnchor" id="H2963639"><span class="h1">CLINICAL SYNDROMES</span><span class="headingEndMark"> — </span>Pneumonia and bacteremia are the most common manifestations of infection [<a href="#rid2">2,4,41,51,52,80-83</a>].</p><p class="headingAnchor" id="H4108514156"><span class="h2">Pulmonary infection</span><span class="headingEndMark"> — </span><em>S. maltophilia</em> pneumonia is usually hospital-acquired and most frequently occurs in mechanically ventilated patients. Antecedent exposure to extended-spectrum penicillin or carbapenem antibiotics is associated with increased risk of ventilator-associated <em>S. maltophilia</em> pneumonia [<a href="#rid84">84</a>]. Compared with pulmonary colonization, infection is more commonly associated with underlying immunosuppression [<a href="#rid85">85</a>]. Clinical and radiographic findings are generally similar to those seen with other infectious causes of hospital-acquired pneumonia. However, in patients with hematologic malignancies, a syndrome of rapidly progressive and frequently fatal hemorrhagic pneumonia associated with <em>S. maltophilia</em> infection has been increasingly reported [<a href="#rid9">9,86,87</a>].</p><p><em>S. maltophilia</em> is a recognized pathogen for cystic fibrosis patients in the United States, with overall prevalence rates similar to those of nontuberculous mycobacteria [<a href="#rid88">88</a>]. <em>S. maltophilia</em> infection correlates with decline in lung function in adult and pediatric cystic fibrosis patients, although causality has not been determined [<a href="#rid89">89,90</a>]. (See  <a class="medical medical_review" href="/z/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Other pathogens'</a>.)</p><p class="headingAnchor" id="H1196897287"><span class="h2">Bacteremia</span><span class="headingEndMark"> — </span>Most cases of <em>S. maltophilia</em> bacteremia are associated with central venous catheters [<a href="#rid3">3,91,92</a>]. As an example, in a study of 207 oncology patients with a central venous catheter and <em>S. maltophilia</em> bloodstream infection, 73 percent of infections were deemed to be catheter-related, 22 percent were secondary (mainly from a pulmonary source), and 5 percent were thought to be primary and noncatheter related [<a href="#rid91">91</a>]. Many catheter-related <em>S. maltophilia</em> bloodstream infections are polymicrobial. Relapse of catheter-associated bacteremia, even up to 200 days after treatment of the initial infection, is also described and has been associated with prolonged neutropenia and catheter retention [<a href="#rid93">93</a>].</p><p>Bacteremia can also be secondary to other types of infections, such as soft tissue infections, urinary tract infections, or severe mucositis in patients with profound neutropenia [<a href="#rid81">81,91,94,95</a>].</p><p class="headingAnchor" id="H131225346"><span class="h2">Other syndromes</span><span class="headingEndMark"> — </span>Less common manifestations of <em>S. maltophilia</em> infections include endocarditis, mastoiditis, peritonitis, meningitis,<sup> </sup>soft tissue infection, wound infection, urinary tract infection, and ocular infection [<a href="#rid2">2,4,41,51,52,81-83,95,96</a>]. <em>Stenotrophomonas</em> can also cause cutaneous manifestations, which may reflect metastatic infiltration or localized infection [<a href="#rid97">97,98</a>]. Reported skin manifestations include cellulitis, infected ulcers, and ecthyma gangrenosum.</p><p class="headingAnchor" id="H3122245367"><span class="h1">MICROBIOLOGIC DIAGNOSIS</span><span class="headingEndMark"> — </span><em>S. maltophilia</em> grows well on commonly used laboratory media, including blood and MacConkey agars, and can be reliably identified in the laboratory using standard biochemical tests (it is lactose nonfermenting, oxidase-negative, and catalase-positive). In addition, it is accurately identified by commercially available automated identification systems [<a href="#rid4">4</a>]. Other techniques for identification include matrix-assisted laser desorption/ionization (MALDI) and nucleic acid amplification, but these tests are not yet standard for many microbiology laboratories.</p><p>The diagnostic evaluation for the specific clinical syndromes caused by <em>S. maltophilia</em> are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1635.html" rel="external">"Clinical presentation and diagnostic evaluation of ventilator-associated pneumonia", section on 'Diagnostic evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/3813.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Clinical manifestations and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H3542155312"><span class="h1">CONSIDERATIONS PRIOR TO SELECTING AN ANTIBIOTIC REGIMEN</span></p><p class="headingAnchor" id="H2258015482"><span class="h2">Differentiating colonization from infection</span><span class="headingEndMark"> — </span><em>S. maltophilia</em> can be readily identified on culture of relevant clinical specimens. However, differentiating colonization from true infection can be difficult and depends on the anatomic site from which the culture sample was obtained and the patient's clinical presentation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cultures from sterile sites</strong> – Growth of the organism from normally sterile sites (eg, blood, pleural fluid, peritoneal fluid, cerebrospinal fluid) should be interpreted as a true infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cultures from nonsterile sites</strong> – Clinical evaluation of the patient is necessary to determine whether a positive culture from a nonsterile site represents true infection. Colonization should not be treated because inappropriate antibiotic use can cause adverse effects and select for resistant organisms.</p><p></p><p class="bulletIndent1">In cases in which the distinction between infection and colonization is uncertain, we recommend initiation of treatment for <em>S. maltophilia</em> until additional clinical information is available. After 48 to 72 hours, we re-evaluate the need for continued <em>S. maltophilia</em> therapy. Treatment recommendations are discussed below. (See <a class="local">'Suggested antibiotic regimens'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Respiratory isolates</strong> – The ability of <em>S. maltophilia </em>to adhere to the surfaces of the upper airway and large bronchi can make it especially difficult to differentiate respiratory colonization from infection.</p><p></p><p class="bulletIndent2">Patients with clinical evidence of pneumonia (eg, new pulmonary infiltrate, decreased oxygenation, and fever and/or leukocytosis) whose respiratory culture grows <em>S. maltophilia</em> (with or without other concurrent respiratory pathogens) should be considered to have true infection.</p><p></p><p class="bulletIndent2">In the absence of consolidation on chest radiography and other clinical signs of pulmonary infection, a positive respiratory tract isolate of <em>Stenotrophomonas</em> probably represents colonization rather than invasive disease. In a retrospective review of 92 patients presenting with acute respiratory symptoms and subsequently found to have respiratory cultures positive for <em>S. maltophilia</em>, there was no measurable impact of antibiotic therapy in patients who did not have chest radiograph consolidation [<a href="#rid99">99</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonrespiratory isolates</strong> – As with respiratory samples, clinicians should use caution when interpreting culture data obtained from other nonsterile sites. Given the organism's propensity to colonize foreign material, cultures from indwelling urinary catheters, surgical drains, and vascular catheter hubs are especially likely to represent colonization.</p><p></p><p class="bulletIndent2">It is critical to assess for clinical evidence of infection, such as fever, leukocytosis, or localized symptoms. In the absence of such findings, the culture findings may be presumed to reflect colonization rather than infection. For example, asymptomatic bacteruria should not be treated in most individuals. (See  <a class="medical medical_review" href="/z/d/html/8061.html" rel="external">"Asymptomatic bacteriuria in adults"</a>.)</p><p></p><p class="headingAnchor" id="H2620406645"><span class="h2">Indications for empiric therapy</span><span class="headingEndMark"> — </span>We suggest covering <em>Stenotrophomonas </em>as part of empiric therapy in certain situations. Primarily, we provide empiric therapy to patients with moderate to severe infection (eg, ventilator-associated pneumonia) who have had prior cultures at the site of infection that grew <em>S. maltophilia</em>. In such cases, we treat with agents that were active against the prior isolates. If the organism ultimately grows from culture, we continue treatment and alter our regimen once susceptibility results return, as described below. (See <a class="local">'Suggested antibiotic regimens'</a> below.)</p><p class="headingAnchor" id="H1503391552"><span class="h2">Assessing the severity of infection</span><span class="headingEndMark"> — </span>Clinical judgement is necessary when categorizing a patient's severity of illness. We typically divide infections in one of two categories:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild infections</strong> – In general, mild infections are those that have good source control and no evidence of severe sepsis or septic shock. Examples include cystitis and tracheitis. Select cases of pneumonia may be categorized as mild if no systemic symptoms (eg, fever &gt;100.5°F/38°C, tachycardia, tachypnea), decrease in baseline oxygenation, or other concerning features are present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate to severe infection</strong> – These infections include any infection for which heightened clinical concern is present or the criteria for mild infection are not met. Examples include more severe cases of pneumonia, severe sepsis or septic shock, undrained abscesses, and catheter-related bloodstream infections for which the catheter has not been removed.</p><p></p><p class="headingAnchor" id="H2292013120"><span class="h1">SUGGESTED ANTIBIOTIC REGIMENS</span><span class="headingEndMark"> — </span>Infections should be treated promptly because a delay in appropriate treatment can contribute to significant mortality. In addition, removal of potential sources of infection (eg, catheter removal or wound debridement) is recommended, if possible [<a href="#rid93">93</a>].</p><p>In general, our recommendations are in accordance with those of expert guidance [<a href="#rid34">34</a>].</p><p>Antibiotic options for treatment of <em>S. maltophilia</em> infections are limited due to high rates of resistance (see <a class="local">'Microbiology'</a> above). Our preferred antibiotic is <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>. We favor it for monotherapy and as the backbone component of combination therapy. Alternatives include <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> and <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a>. Other less favorable options include <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">tigecycline</a> and <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">cefiderocol</a>. Detailed regimens and their efficacy are discussed below. (See <a class="local">'Mild infections in immunocompetent patients'</a> below and <a class="local">'Moderate to severe infections and infections in immunocompromised hosts'</a> below and <a class="local">'Antibiotic efficacy and safety'</a> below.)</p><p>In general, we select antibiotic regimens based on the severity of illness and immune status of the patient (<a class="graphic graphic_algorithm graphicRef139798" href="/z/d/graphic/139798.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H342757620"><span class="h2">Mild infections in immunocompetent patients</span><span class="headingEndMark"> — </span>For mild infections in immunocompetent patients, we typically suggest monotherapy based on the results of the isolate's antibiotic susceptibility testing.</p><p>Treatment options include the following (doses listed are for patients with normal renal function) (<a class="graphic graphic_algorithm graphicRef139798" href="/z/d/graphic/139798.html" rel="external">algorithm 1</a>) [<a href="#rid34">34</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">Trimethoprim-sulfamethoxazole</a> (preferred)</p><p></p><p class="bulletIndent1">For infections other than cystitis, the typical dose is 8 to 12 mg/kg/day of the <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a> component intravenously in 2 or 3 divided doses, with a maximum dose of 960 mg of trimethoprim component per day. An equivalent oral dosage is two double-strength tablets every 12 hours for a patient who weighs 70 kg.</p><p></p><p class="bulletIndent1">For cystitis, one double-strength tablet every 12 hours is appropriate. An equivalent parenteral dose is 160 mg (<a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a> component) intravenously every 12 hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">Minocycline</a> 200 mg intravenously or orally every 12 hours (alternative). Minocycline is not recommended as monotherapy for UTIs or bacteremia due to low concentrations in the blood and urine. (See <a class="local">'Alternative antibiotics'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">Levofloxacin</a> 750 mg intravenously or orally once daily (alternative)</p><p></p><p>If none of the above three agents is an option due to resistance or intolerance, options include <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">tigecycline</a> (200 mg intravenously for one dose, then 100 mg intravenously every 12 hours) or <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">cefiderocol</a> (2 g intravenously every eight hours). Tigecycline is not recommended as monotherapy for UTIs or bacteremia due to low concentrations in the blood and urine, and it is not recommended for monotherapy for hospital-acquired pneumonia due to data suggesting worse outcomes (<a class="graphic graphic_algorithm graphicRef139798" href="/z/d/graphic/139798.html" rel="external">algorithm 1</a>) [<a href="#rid100">100</a>]. (See <a class="local">'Alternative antibiotics'</a> below.)</p><p>Discussion of the safety and efficacy of these regimens is found below. (See <a class="local">'Antibiotic efficacy and safety'</a> below.)</p><p class="headingAnchor" id="H4275874253"><span class="h2">Moderate to severe infections and infections in immunocompromised hosts</span><span class="headingEndMark"> — </span>Consistent with the Infectious Diseases Society of America (IDSA) guidelines, we generally suggest initial combination therapy for moderate to severe infections and infections in immunocompromised hosts, though clinical outcomes data comparing monotherapy to combination therapy are limited and have conflicting results [<a href="#rid59">59,101</a>]. In one prospective study of patients with <em>S. maltophilia</em> bacteremia, receipt of two or more of <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX), a third generation cephalosporin, and an extended-spectrum penicillin was associated with lower mortality rates compared with receipt of just one agent [<a href="#rid59">59</a>]. In contrast, a retrospective study of 252 patients with <em>S. maltophilia </em>pneumonia found no difference in outcomes with combination therapy versus monotherapy [<a href="#rid101">101</a>]. The evidence for combination therapy resides predominantly in in vitro studies that have reported in vitro synergy for TMP-SMX plus a second agent (including <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, fluoroquinolones, and <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">cefiderocol</a>, as well as other agents) [<a href="#rid102">102-109</a>].</p><p>The choice of agents is based on the results of the isolate's susceptibility testing and factors specific to the clinical scenario including any known antibiotic intolerances, patient-specific antibiotic risk assessment, and need for concomitant antibacterial coverage for other infections. Consultation with an expert in these infections is advised (<a class="graphic graphic_algorithm graphicRef139798" href="/z/d/graphic/139798.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preferred regimens for combination therapy</strong> – For combination therapy, we prefer to include TMP-SMX if the isolate is susceptible and there are no contraindications.</p><p></p><p class="bulletIndent1">Our preferred combination is TMP-SMX plus <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>. If minocycline is not an option, then <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a>, <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">tigecycline</a>, or <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">cefiderocol</a> may be added to TMP-SMX as second agents. Dosages are the same as those described above for mild infections. (See <a class="local">'Mild infections in immunocompetent patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Regimens if </strong><a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a><strong> is not an option</strong> – For these situations, we favor a combination of <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> and <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a>, if the isolate is susceptible to both agents. Dosages are listed above. (See <a class="local">'Mild infections in immunocompetent patients'</a> above.)</p><p></p><p class="bulletIndent1">If the combination of <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> and <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a> is not an option, and TMP-SMX can't be administered because the patient has an immunoglobulin (Ig)E-mediated hypersensitivity reaction, we favor rapid desensitization to TMP-SMX if the isolate is susceptible [<a href="#rid110">110</a>]. After desensitization, we choose one of the TMP-SMX-based regimens listed above. The technique for desensitizing patients is discussed in detail elsewhere [<a href="#rid7">7,110</a>]. (See  <a class="medical medical_review" href="/z/d/html/2071.html" rel="external">"Rapid drug desensitization for immediate hypersensitivity reactions"</a> and  <a class="medical medical_review" href="/z/d/html/2080.html" rel="external">"Sulfonamide allergy in HIV-uninfected patients", section on 'Desensitization'</a>.)</p><p></p><p class="bulletIndent1">If neither the combination of <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> and <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a> nor TMP-SMX desensitization are options, then other combinations of minocycline, levofloxacin, <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">cefiderocol</a>, and <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">tigecycline</a> may be selected, depending on the site of infection and patient-specific factors. Once appropriate clinical response has occurred, we narrow the antibiotic regimen to a single active agent.</p><p></p><p class="bulletIndent1">In the rare event that none of the above options can be used, limited in vitro and in vivo data indicate the combination of <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a> plus <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a> may be effective and may be trialed as a salvage regimen (<a class="graphic graphic_algorithm graphicRef139798" href="/z/d/graphic/139798.html" rel="external">algorithm 1</a>) [<a href="#rid111">111-115</a>].</p><p></p><p class="bulletIndent1">Discussion of the safety and efficacy of these regimens is found below. (See <a class="local">'Antibiotic efficacy and safety'</a> below.)</p><p></p><p class="headingAnchor" id="H849063763"><span class="h1">ANTIBIOTIC EFFICACY AND SAFETY</span><span class="headingEndMark"> — </span>Inherent and acquired resistance limits the number of antimicrobial options for <em>S. maltophilia</em>. Clinical data are limited regarding optimal therapy, and most available data are derived from observational and in vitro studies.</p><p class="headingAnchor" id="H976024920"><span class="h2">Trimethoprim-sulfamethoxazole as the preferred option</span><span class="headingEndMark"> — </span>The preferred antibiotic for treatment of <em>S. maltophilia </em>infections is <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX). Specific TMP-SMX-based regimens for treatment of <em>S. maltophilia </em>are found elsewhere. (See <a class="local">'Suggested antibiotic regimens'</a> above.)</p><p>There is extensive clinical experience with TMP-SMX, and observational studies and case series report somewhat favorable clinical outcomes [<a href="#rid59">59,116-120</a>]. In observational studies, in-hospital or 30-day mortality rates ranged between 21 and 31 percent with monotherapy with TMP-SMX [<a href="#rid59">59,116,117</a>]. Outcomes were similar when compared with other antimicrobials.</p><p>This agent has the most reliable in vitro activity against <em>S. maltophilia</em> [<a href="#rid121">121-124</a>]. As an example, in a surveillance study of gram-negative organisms isolated from patients hospitalized with pneumonia between 2009 and 2012, susceptibility to TMP-SMX was documented for 96 percent of the 302 <em>S. maltophilia</em> isolates from United States hospitals and 98 percent of the 192 isolates from European hospitals [<a href="#rid121">121</a>]. However, in vitro resistance to TMP-SMX among <em>S. maltophilia</em> isolates has been increasingly reported, particularly in patients with cystic fibrosis [<a href="#rid51">51,80,125,126</a>].</p><p>Resistance to TMP-SMX can develop during therapy. In observational studies, the rates of resistance at the end of therapy with TMP-SMX ranged from 7 to 10 percent [<a href="#rid116">116,119</a>]. Although concerning, these rates are not as high as with other agents such as fluoroquinolones.</p><p>Some patients are unable to tolerate TMP-SMX due to hypersensitivity reaction, drug toxicity, or another adverse reaction. In some situations, desensitization may allow the administration of TMP-SMX, as discussed above. (See <a class="local">'Moderate to severe infections and infections in immunocompromised hosts'</a> above and  <a class="medical medical_review" href="/z/d/html/2080.html" rel="external">"Sulfonamide allergy in HIV-uninfected patients"</a>.)</p><p class="headingAnchor" id="H3589859013"><span class="h2">Alternative antibiotics</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">Tetracycline</a> derivatives (ie, <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> and <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">tigecycline</a>) and fluoroquinolones (ie, <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a>) are favored for infections for which TMP-SMX is not an option or for combination therapy with TMP-SMX.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">Tetracycline</a><strong> derivatives</strong> – <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">Minocycline</a> and <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">tigecycline</a> are alternatives to <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> for treatment of <em>S. maltophilia</em>. We favor minocycline over tigecycline due to minocycline's more favorable in vitro<em> </em>data, availability of an oral formulation, standardized breakpoints for reporting susceptibility, and better tolerability. Specific regimens for treatment of <em>S. maltophilia </em>are found elsewhere. (See <a class="local">'Suggested antibiotic regimens'</a> above.)</p><p></p><p class="bulletIndent1">For treatment of bloodstream infections and urinary tract infections, we only use these agents as part of combination therapy because both <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> and <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">tigecycline</a> achieve suboptimal drug levels in the blood and urine [<a href="#rid34">34</a>]. For hospital-acquired pneumonia, tigecycline monotherapy is not advised due to concerns about higher mortality rates compared with other agents [<a href="#rid100">100</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">Minocycline</a> and <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">tigecycline</a> have both been shown in small retrospective studies to be associated with clinical outcomes that are comparable to those with TMP-SMX [<a href="#rid117">117,118,127</a>]. In one study of 93 hospitalized patients with <em>S. maltophilia </em>infection treated with minocycline, 17 (18 percent) experienced clinical failure, defined as death within 30 days or clinical deterioration [<a href="#rid127">127</a>]. In another study of 19 hospitalized patients treated with tigecycline, six (32 percent) had clinical failure [<a href="#rid117">117</a>].</p><p></p><p class="bulletIndent1">The majority of <em>S. maltophilia </em>isolates are susceptible to both <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> and <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">tigecycline</a> [<a href="#rid121">121,122,128</a>]. For example, in a surveillance study of 494 isolates of <em>S. maltophilia</em> from patients hospitalized with <em>S. maltophilia </em>pneumonia between 2009 and 2012 in the United States and Europe, susceptibility to minocycline was 99 percent [<a href="#rid121">121</a>]. In a separate study of 80 clinical isolates, 67 (84 percent) were susceptible to tigecycline [<a href="#rid109">109</a>]. Most isolates that were resistant to TMP-SMX retained susceptibility to minocycline and tigecycline.</p><p></p><p class="bulletIndent1">Clinical data are scarce for <a class="drug drug_general" data-topicid="118878" href="/z/d/drug information/118878.html" rel="external">eravacycline</a>, another <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> derivative with low minimal inhibitory concentrations (MICs) when tested against <em>S. maltophilia </em>[<a href="#rid129">129</a>]<em>. </em><a class="drug drug_general" data-topicid="119253" href="/z/d/drug information/119253.html" rel="external">Omadacycline</a> has limited in vitro activity against <em>S. maltophilia. </em>These agents are not recommended for treatment of <em>S. maltophilia </em>infections at this time.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluoroquinolones</strong> – These agents, in particular <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a>, are potential alternatives to TMP-SMX [<a href="#rid122">122</a>]. Specific levofloxacin-based regimens for treatment of <em>S. maltophilia </em>are found elsewhere. (See <a class="local">'Suggested antibiotic regimens'</a> above.)</p><p></p><p class="bulletIndent1">Retrospective studies, including one that evaluated over 1500 patients from 154 United States hospitals, have suggested similar clinical outcomes (microbiologic cure, clinical success, and short-term mortality rates) in <em>S. maltophilia</em> infection with fluoroquinolone versus TMP-SMX monotherapy [<a href="#rid116">116,119,120,130,131</a>]. Furthermore, a systematic review and meta-analysis that included 663 patients treated either with TMP-SMX or fluoroquinolone monotherapy found comparable effects on mortality between the two groups [<a href="#rid116">116,119,120,132,133</a>].</p><p></p><p class="bulletIndent1">Baseline susceptibility rates of <em>S. maltophilia </em>to <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a> vary from 30 to 80 percent in surveillance studies [<a href="#rid56">56,103,109,121</a>]. In addition, in vitro and observational studies raise concern about emergence of resistance during treatment with fluoroquinolones [<a href="#rid116">116,119,132,133</a>]. In clinical observational studies, 19 to 27 percent of patients treated with fluoroquinolones had fluoroquinolone-resistant isolates at the end of therapy [<a href="#rid116">116,119</a>].</p><p></p><p class="bulletIndent1">Although data suggest that <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a> may have similar in vitro activity as <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a> against <em>S. maltophilia </em>[<a href="#rid134">134</a>], there are no Clinical and Laboratory Standards Institute (CLSI)-defined breakpoints for moxifloxacin or <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a>. Therefore, it is our practice to preferentially use levofloxacin rather than other fluoroquinolones for treatment of <em>S. maltophilia</em> infections.</p><p></p><p class="headingAnchor" id="H867879135"><span class="h2">Other antibiotic options</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">Cefiderocol</a> – Preclinical data suggest that cefiderocol appears to have reliable in vitro activity against <em>S. maltophilia,</em> but clinical data are limited [<a href="#rid103">103,135</a>]. In a trial of cefiderocol for the treatment of multidrug-resistant gram-negative bacilli infections, only five patients with <em>S. maltophilia </em>infection (pneumonia) were included, and <em>S. maltophilia</em>-specific outcomes were not reported [<a href="#rid136">136,137</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination therapy with </strong><a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a><strong> and </strong><a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a> – Ceftazidime-avibactam is a novel beta-lactam/beta-lactamase inhibitor that has limited in vitro activity against <em>S. maltophilia. </em>However, the avibactam component of the drug is able to overcome the resistance mechanism to aztreonam, rendering aztreonam effective against many <em>S. maltophilia </em>isolates [<a href="#rid111">111,112,138-140</a>]. The combination has been reported to lead to successful clinical outcomes in a few case reports [<a href="#rid113">113-115</a>].</p><p></p><p class="headingAnchor" id="H1608773265"><span class="h2">Antibiotics that should not be used</span><span class="headingEndMark"> — </span><em>S. maltophilia</em> is intrinsically resistant to a number of antibiotics that are commonly used to treat multidrug-resistant gram-negative bacilli, including traditional beta-lactam antibiotics (eg, <a class="drug drug_general" data-topicid="8745" href="/z/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a>, <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>, <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>), <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a> monotherapy, carbapenems, aminoglycosides, <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">fosfomycin</a>, and other novel agents (eg, <a class="drug drug_general" data-topicid="119253" href="/z/d/drug information/119253.html" rel="external">omadacycline</a>, <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a>, <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a>, <a class="drug drug_general" data-topicid="114672" href="/z/d/drug information/114672.html" rel="external">meropenem-vaborbactam</a>, imipenem-relebactam, <a class="drug drug_general" data-topicid="118322" href="/z/d/drug information/118322.html" rel="external">plazomicin</a>) [<a href="#rid34">34,141</a>].</p><p></p><p>Although some isolates of <em>S. maltophilia </em>are reported to be susceptible to <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a> and carbapenems, intrinsic resistance mechanisms are felt to render these agents ineffective [<a href="#rid121">121,122,129</a>]. In vitro data suggest that ceftazidime is unable to control growth of the organism [<a href="#rid109">109</a>]. Expert panels suggest that ceftazidime and carbapenems should not be used to treat <em>S. maltophilia </em>infections, even if the isolate is reported as susceptible by the microbiology laboratory [<a href="#rid34">34,142,143</a>].</p><p>Polymyxins (eg, <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">colistin</a> sulfate) have variable rates of in vitro activity against <em>S. maltophilia</em>. In the United States, no CLSI criteria exist to determine polymyxin susceptibility in microbiology labs, and the accuracy and reliability of polymyxin MICs are uncertain [<a href="#rid34">34,144-146</a>]. Given these concerns, we do not use polymyxins to treat <em>S. maltophilia</em> infections<em>.</em></p><p>Ticarcillin-clavulanic acid resistance is common (up to 55 percent) [<a href="#rid18">18,41,147</a>], and the drug is unavailable in most countries, including the United States and Canada.</p><p class="headingAnchor" id="H3003848604"><span class="h1">DURATION OF THERAPY</span><span class="headingEndMark"> — </span>In general, the duration of therapy for <em>S. maltophilia </em>infections is the same as that for other gram-negative bacilli.</p><p>The duration primarily depends on the site of infection. For bacteremia<em>, </em>we favor 14 days of therapy. Although studies have suggested that shorter courses are similarly effective for gram-negative bacillary bacteremia, <em>S. maltophilia </em>was not well represented in those studies. Further discussion of gram-negative bacteremia is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3149.html" rel="external">"Gram-negative bacillary bacteremia in adults", section on 'Duration and route of therapy'</a>.)</p><p class="headingAnchor" id="H465013486"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span><em>S. maltophilia</em> infections have been associated with high morbidity and mortality in severely immunocompromised and debilitated individuals.</p><p>Overall, mortality estimates range from 21 to 69 percent [<a href="#rid60">60,148-150</a>]. However, the actual mortality attributed to these infections when controlling for other variables is unclear.</p><p>Retrospective analyses have reported the following risk factors for increased mortality: admission to an intensive care unit (ICU), delay in appropriate treatment, hematologic malignancy, and immunosuppression [<a href="#rid2">2,59</a>].</p><p class="headingAnchor" id="H101330444"><span class="h1">INFECTION CONTROL AND PREVENTION</span><span class="headingEndMark"> — </span>Infection control and antibiotic stewardship measures are important to minimize the incidence of <em>S. maltophilia</em> infections and for reducing emergence of resistant strains. These measures include appropriate use of antibiotics, avoidance of prolonged or unnecessary use of foreign devices, and adherence to hand hygiene practices. Strict hand hygiene and contact isolation procedures have been utilized to reduce clonal spread in the intensive care unit (ICU) setting [<a href="#rid151">151</a>]. (See  <a class="medical medical_review" href="/z/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection"</a>.)</p><p class="headingAnchor" id="H2964717"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology</strong> – <em>Stenotrophomonas maltophilia</em> is a multidrug-resistant gram-negative bacillus that is an opportunistic pathogen. (See <a class="local">'Microbiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Infection typically occurs in severely immunocompromised and debilitated individuals. Specific risk factors include admission to an intensive care unit (ICU), HIV infection, malignancy, cystic fibrosis, neutropenia, mechanical ventilation, central venous catheter, recent surgery, trauma, and previous therapy with broad-spectrum antibiotics. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical syndromes</strong> – Pneumonia (usually hospital-acquired) and bacteremia (often associated with an indwelling catheter) are the most common manifestations of <em>S. maltophilia</em> infection. Less common manifestations include endocarditis, mastoiditis, peritonitis, meningitis,<sup> </sup>soft tissue infection, wound infection, urinary tract infection, and ocular infection. (See <a class="local">'Clinical syndromes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis and differentiating colonization from infection</strong> – Growth of <em>S. maltophilia</em> from normally sterile sites (eg, blood, pleural fluid, peritoneal fluid) should be interpreted to represent true infection. In patients with clinical evidence of pneumonia, cultures growing <em>S. maltophilia</em> from respiratory sites should be interpreted as consistent with infection. Similarly, culture data obtained from other nonsterile sites (eg, indwelling catheters or drains) must consider patients' clinical findings to differentiate colonization from infection. (See <a class="local">'Differentiating colonization from infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic therapy</strong> – The selection of antibiotic regimens depends primarily on the severity of illness and immune status of the patient (<a class="graphic graphic_algorithm graphicRef139798" href="/z/d/graphic/139798.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild infections in immunocompetent individuals</strong> – For empiric and directed therapy of mild <em>S. maltophilia</em> infections, we suggest monotherapy with <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). If TMP-SMX is not an option, appropriate alternatives include <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> or <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a>. TMP-SMX is preferred because it has the most clinical experience and most reliable in vitro activity (<a class="graphic graphic_algorithm graphicRef139798" href="/z/d/graphic/139798.html" rel="external">algorithm 1</a>). (See <a class="local">'Mild infections in immunocompetent patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Moderate to severe infections and infections in immunocompromised patients</strong> – For these patients, we suggest initial combination therapy with a TMP-SMX plus <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). If minocycline can't be used (eg, because of intolerance or resistance), <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a> is an alternative to use with TMP-SMX. Data for combination therapy are very limited, but some studies suggest that it may be associated with lower mortality (<a class="graphic graphic_algorithm graphicRef139798" href="/z/d/graphic/139798.html" rel="external">algorithm 1</a>). (See <a class="local">'Moderate to severe infections and infections in immunocompromised hosts'</a> above.)</p><p></p><p class="bulletIndent2">Other antibiotic options with activity against <em>S. maltophilia </em>include <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">tigecycline</a>, <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">cefiderocol</a>, or the combination of <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a> plus <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a>; clinical data are limited for these agents (<a class="graphic graphic_algorithm graphicRef139798" href="/z/d/graphic/139798.html" rel="external">algorithm 1</a>). (See <a class="local">'Suggested antibiotic regimens'</a> above.)</p><p></p><p class="bulletIndent1">Certain infections may warrant additional interventions, such as catheter removal or wound debridement. (See <a class="local">'Assessing the severity of infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of therapy</strong> – In general, the duration of therapy for <em>S. maltophilia </em>infections is the same as that for other gram-negative bacilli. The duration primarily depends on the site of infection. For bacteremia<em>, </em>we suggest 14 days of therapy rather than shorter durations (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Duration of therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection control and prevention</strong> – To minimize the incidence of <em>S. maltophilia</em> infections and reduce the emergence of resistant strains, judicious use of antibiotics, avoidance of prolonged or unnecessary use of foreign devices, and adherence to hand hygiene practices are necessary. (See <a class="local">'Infection control and prevention'</a> above and  <a class="medical medical_review" href="/z/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Paez JI, Tengan FM, Barone AA, et al. Factors associated with mortality in patients with bloodstream infection and pneumonia due to Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis 2008; 27:901.</a></li><li><a class="nounderline abstract_t">Kwa AL, Low JG, Lim TP, et al. Independent predictors for mortality in patients with positive Stenotrophomonas maltophilia cultures. Ann Acad Med Singapore 2008; 37:826.</a></li><li><a class="nounderline abstract_t">Lai CH, Chi CY, Chen HP, et al. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J Microbiol Immunol Infect 2004; 37:350.</a></li><li><a class="nounderline abstract_t">Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998; 11:57.</a></li><li><a class="nounderline abstract_t">Calza L, Manfredi R, Chiodo F. Stenotrophomonas (Xanthomonas) maltophilia as an emerging opportunistic pathogen in association with HIV infection: a 10-year surveillance study. Infection 2003; 31:155.</a></li><li class="breakAll">Giligan P, Lum G, Vandamme PAR, Whittier S. Burkholderia, Stenotrophomonas, Ralstonia, Brevundimonas, Comamonas, Delftia, Pandoraea, and Acidovorax. In: Manual of Clinical Microbiology, 8th, Murray PR (Ed), ASM, Washington 2003.</li><li><a class="nounderline abstract_t">Looney WJ, Narita M, Mühlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis 2009; 9:312.</a></li><li><a class="nounderline abstract_t">Crossman LC, Gould VC, Dow JM, et al. The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants. Genome Biol 2008; 9:R74.</a></li><li><a class="nounderline abstract_t">Elsner HA, Dührsen U, Hollwitz B, et al. Fatal pulmonary hemorrhage in patients with acute leukemia and fulminant pneumonia caused by Stenotrophomonas maltophilia. Ann Hematol 1997; 74:155.</a></li><li><a class="nounderline abstract_t">Ganadu M, Mura GL, Campus AM, et al. Relapsing pyrogenic reactions due to Xanthomonas maltophilia in a dialysis patient with a long-term central venous catheter. Nephrol Dial Transplant 1996; 11:197.</a></li><li><a class="nounderline abstract_t">Girijaratnakumari T, Raja A, Ramani R, et al. Meningitis due to Xanthomonas maltophilia. J Postgrad Med 1993; 39:153.</a></li><li><a class="nounderline abstract_t">Lo WT, Wang CC, Lee CM, Chu ML. Successful treatment of multi-resistant Stenotrophomonas maltophilia meningitis with ciprofloxacin in a pre-term infant. Eur J Pediatr 2002; 161:680.</a></li><li><a class="nounderline abstract_t">Papadakis KA, Vartivarian SE, Vassilaki ME, Anaissie EJ. Stenotrophomonas maltophilia: an unusual cause of biliary sepsis. Clin Infect Dis 1995; 21:1032.</a></li><li><a class="nounderline abstract_t">Papadakis KA, Vartivarian SE, Vassilaki ME, Anaissie EJ. Septic prepatellar bursitis caused by Stenotrophomonas (Xanthomonas) maltophilia. Clin Infect Dis 1996; 22:388.</a></li><li><a class="nounderline abstract_t">Smeets JG, Löwe SH, Veraart JC. Cutaneous infections with Stenotrophomonas maltophilia in patients using immunosuppressive medication. J Eur Acad Dermatol Venereol 2007; 21:1298.</a></li><li><a class="nounderline abstract_t">Gilardi GL. Infrequently encountered Pseudomonas species causing infection in humans. Ann Intern Med 1972; 77:211.</a></li><li><a class="nounderline abstract_t">Khardori N, Elting L, Wong E, et al. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis 1990; 12:997.</a></li><li><a class="nounderline abstract_t">Nicodemo AC, Paez JI. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis 2007; 26:229.</a></li><li><a class="nounderline abstract_t">Gilardi GL. Pseudomonas maltophilia infections in man. Am J Clin Pathol 1969; 51:58.</a></li><li><a class="nounderline abstract_t">Elting LS, Khardori N, Bodey GP, Fainstein V. Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol 1990; 11:134.</a></li><li><a class="nounderline abstract_t">Falagas ME, Kastoris AC, Vouloumanou EK, et al. Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature. Future Microbiol 2009; 4:1103.</a></li><li><a class="nounderline abstract_t">Bottone EJ, Reitano M, Janda JM, et al. Pseudomonas maltophilia exoenzyme activity as correlate in pathogenesis of ecthyma gangrenosum. J Clin Microbiol 1986; 24:995.</a></li><li><a class="nounderline abstract_t">Jucker BA, Harms H, Zehnder AJ. Adhesion of the positively charged bacterium Stenotrophomonas (Xanthomonas) maltophilia 70401 to glass and Teflon. J Bacteriol 1996; 178:5472.</a></li><li><a class="nounderline abstract_t">de Oliveira-Garcia D, Dall'Agnol M, Rosales M, et al. Fimbriae and adherence of Stenotrophomonas maltophilia to epithelial cells and to abiotic surfaces. Cell Microbiol 2003; 5:625.</a></li><li><a class="nounderline abstract_t">Di Bonaventura G, Spedicato I, D'Antonio D, et al. Biofilm formation by Stenotrophomonas maltophilia: modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime. Antimicrob Agents Chemother 2004; 48:151.</a></li><li><a class="nounderline abstract_t">Martínez JL, Baquero F. Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance. Clin Microbiol Rev 2002; 15:647.</a></li><li><a class="nounderline abstract_t">de Oliveira-Garcia D, Dall'Agnol M, Rosales M, et al. Characterization of flagella produced by clinical strains of Stenotrophomonas maltophilia. Emerg Infect Dis 2002; 8:918.</a></li><li><a class="nounderline abstract_t">Waters VJ, Gómez MI, Soong G, et al. Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia. Infect Immun 2007; 75:1698.</a></li><li><a class="nounderline abstract_t">Avison MB, Higgins CS, von Heldreich CJ, et al. Plasmid location and molecular heterogeneity of the L1 and L2 beta-lactamase genes of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2001; 45:413.</a></li><li><a class="nounderline abstract_t">Crowder MW, Walsh TR, Banovic L, et al. Overexpression, purification, and characterization of the cloned metallo-beta-lactamase L1 from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 1998; 42:921.</a></li><li><a class="nounderline abstract_t">Saino Y, Inoue M, Mitsuhashi S. Purification and properties of an inducible cephalosporinase from Pseudomonas maltophilia GN12873. Antimicrob Agents Chemother 1984; 25:362.</a></li><li><a class="nounderline abstract_t">Walsh TR, MacGowan AP, Bennett PM. Sequence analysis and enzyme kinetics of the L2 serine beta-lactamase from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 1997; 41:1460.</a></li><li><a class="nounderline abstract_t">Mojica MF, Rutter JD, Taracila M, et al. Population Structure, Molecular Epidemiology, and β-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United States. mBio 2019; 10.</a></li><li class="breakAll">Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America (IDSA). Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 2.0. https://www.idsociety.org/practice-guideline/amr-guidance-2.0/ (Accessed on August 17, 2022).</li><li><a class="nounderline abstract_t">Spencer RC. The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia. J Hosp Infect 1995; 30 Suppl:453.</a></li><li><a class="nounderline abstract_t">Hancock RE. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis 1998; 27 Suppl 1:S93.</a></li><li><a class="nounderline abstract_t">Lambert T, Ploy MC, Denis F, Courvalin P. Characterization of the chromosomal aac(6')-Iz gene of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 1999; 43:2366.</a></li><li><a class="nounderline abstract_t">Li XZ, Zhang L, McKay GA, Poole K. Role of the acetyltransferase AAC(6')-Iz modifying enzyme in aminoglycoside resistance in Stenotrophomonas maltophilia. J Antimicrob Chemother 2003; 51:803.</a></li><li><a class="nounderline abstract_t">Poole K. Outer membranes and efflux: the path to multidrug resistance in Gram-negative bacteria. Curr Pharm Biotechnol 2002; 3:77.</a></li><li><a class="nounderline abstract_t">Safdar A, Rolston KV. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis 2007; 45:1602.</a></li><li><a class="nounderline abstract_t">Falagas ME, Valkimadi PE, Huang YT, et al. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J Antimicrob Chemother 2008; 62:889.</a></li><li><a class="nounderline abstract_t">Wheat PF, Winstanley TG, Spencer RC. Effect of temperature on antimicrobial susceptibilities of Pseudomonas maltophilia. J Clin Pathol 1985; 38:1055.</a></li><li><a class="nounderline abstract_t">Rahmati-Bahram A, Magee JT, Jackson SK. Growth temperature-dependent variation of cell envelope lipids and antibiotic susceptibility in Stenotrophomonas (Xanthomonas) maltophilia. J Antimicrob Chemother 1995; 36:317.</a></li><li><a class="nounderline abstract_t">Rahmati-Bahram A, Magee JT, Jackson SK. Temperature-dependent aminoglycoside resistance in Stenotrophomonas (Xanthomonas) maltophilia; alterations in protein and lipopolysaccharide with growth temperature. J Antimicrob Chemother 1996; 37:665.</a></li><li><a class="nounderline abstract_t">Rahmati-Bahram A, Magee JT, Jackson SK. Effect of temperature on aminoglycoside binding sites in Stenotrophomonas maltophilia. J Antimicrob Chemother 1997; 39:19.</a></li><li><a class="nounderline abstract_t">Alonso A, Martínez JL. Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2000; 44:3079.</a></li><li><a class="nounderline abstract_t">Alonso A, Martinez JL. Expression of multidrug efflux pump SmeDEF by clinical isolates of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2001; 45:1879.</a></li><li><a class="nounderline abstract_t">Zhang L, Li XZ, Poole K. Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia. J Antimicrob Chemother 2001; 48:549.</a></li><li><a class="nounderline abstract_t">Alonso A, Sanchez P, Martínez JL. Stenotrophomonas maltophilia D457R contains a cluster of genes from gram-positive bacteria involved in antibiotic and heavy metal resistance. Antimicrob Agents Chemother 2000; 44:1778.</a></li><li><a class="nounderline abstract_t">del Toro MD, Rodríguez-Bano J, Herrero M, et al. Clinical epidemiology of Stenotrophomonas maltophilia colonization and infection: a multicenter study. Medicine (Baltimore) 2002; 81:228.</a></li><li><a class="nounderline abstract_t">Al-Jasser AM. Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem. Ann Clin Microbiol Antimicrob 2006; 5:23.</a></li><li><a class="nounderline abstract_t">Köseoğlu O, Sener B, Gülmez D, et al. Stenotrophomonas maltophilia as a nosocomial pathogen. New Microbiol 2004; 27:273.</a></li><li><a class="nounderline abstract_t">Pankuch GA, Jacobs MR, Rittenhouse SF, Appelbaum PC. Susceptibilities of 123 strains of Xanthomonas maltophilia to eight beta-lactams (including beta-lactam-beta-lactamase inhibitor combinations) and ciprofloxacin tested by five methods. Antimicrob Agents Chemother 1994; 38:2317.</a></li><li><a class="nounderline abstract_t">Giamarellos-Bourboulis EJ, Karnesis L, Galani I, Giamarellou H. In vitro killing effect of moxifloxacin on clinical isolates of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 2002; 46:3997.</a></li><li class="breakAll">Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: Eighteenth informational supplement [Document M100-S18]. Wayne, PA 2008.</li><li><a class="nounderline abstract_t">Farrell DJ, Sader HS, Jones RN. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother 2010; 54:2735.</a></li><li class="breakAll">The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0, 2016. http://www.eucast.org (Accessed on December 02, 2016).</li><li><a class="nounderline abstract_t">Morrison AJ Jr, Hoffmann KK, Wenzel RP. Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital. J Clin Microbiol 1986; 24:52.</a></li><li><a class="nounderline abstract_t">Muder RR, Harris AP, Muller S, et al. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis 1996; 22:508.</a></li><li><a class="nounderline abstract_t">Paez JI, Costa SF. Risk factors associated with mortality of infections caused by Stenotrophomonas maltophilia: a systematic review. J Hosp Infect 2008; 70:101.</a></li><li><a class="nounderline abstract_t">Victor MA, Arpi M, Bruun B, et al. Xanthomonas maltophilia bacteremia in immunocompromised hematological patients. Scand J Infect Dis 1994; 26:163.</a></li><li><a class="nounderline abstract_t">Carmeli Y, Samore MH. Comparison of treatment with imipenem vs. ceftazidime as a predisposing factor for nosocomial acquisition of Stenotrophomonas maltophilia: a historical cohort study. Clin Infect Dis 1997; 24:1131.</a></li><li><a class="nounderline abstract_t">Falagas ME, Kastoris AC, Vouloumanou EK, Dimopoulos G. Community-acquired Stenotrophomonas maltophilia infections: a systematic review. Eur J Clin Microbiol Infect Dis 2009; 28:719.</a></li><li><a class="nounderline abstract_t">Guyot A, Turton JF, Garner D. Outbreak of Stenotrophomonas maltophilia on an intensive care unit. J Hosp Infect 2013; 85:303.</a></li><li><a class="nounderline abstract_t">Alfieri N, Ramotar K, Armstrong P, et al. Two consecutive outbreaks of Stenotrophomonas maltophilia (Xanthomonas maltophilia) in an intensive-care unit defined by restriction fragment-length polymorphism typing. Infect Control Hosp Epidemiol 1999; 20:553.</a></li><li><a class="nounderline abstract_t">Weber DJ, Rutala WA, Blanchet CN, et al. Faucet aerators: A source of patient colonization with Stenotrophomonas maltophilia. Am J Infect Control 1999; 27:59.</a></li><li><a class="nounderline abstract_t">Labarca JA, Leber AL, Kern VL, et al. Outbreak of Stenotrophomonas maltophilia bacteremia in allogenic bone marrow transplant patients: role of severe neutropenia and mucositis. Clin Infect Dis 2000; 30:195.</a></li><li><a class="nounderline abstract_t">Sakhnini E, Weissmann A, Oren I. Fulminant Stenotrophomonas maltophilia soft tissue infection in immunocompromised patients: an outbreak transmitted via tap water. Am J Med Sci 2002; 323:269.</a></li><li><a class="nounderline abstract_t">Hench C, Johnson N, Reyes V, et al. Outbreak of Stenotrophomonas maltophilia bloodstream infections in an outpatient dialysis center. Am J Infect Control 2007; 35:E130.</a></li><li><a class="nounderline abstract_t">Verweij PE, Meis JF, Christmann V, et al. Nosocomial outbreak of colonization and infection with Stenotrophomonas maltophilia in preterm infants associated with contaminated tap water. Epidemiol Infect 1998; 120:251.</a></li><li><a class="nounderline abstract_t">Çetin BS, Çelebi S, Özkan H, et al. Stenotrophomonas maltophilia outbreak in neonatal intensive care unit and outbreak management. J Pediatr Inf 2015; 9:147.</a></li><li><a class="nounderline abstract_t">Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev 2012; 25:2.</a></li><li><a class="nounderline abstract_t">Wang C, Hsu S, Tsai T, Wang N. An outbreak of trimethoprim/sulfamethoxazole-resistant Stenotrophomonas maltophilia meningitis associated with neuroendoscopy. J Med Sci 2014; 34:235.</a></li><li><a class="nounderline abstract_t">Guy M, Vanhems P, Dananché C, et al. Outbreak of pulmonary Pseudomonas aeruginosa and Stenotrophomonas maltophilia infections related to contaminated bronchoscope suction valves, Lyon, France, 2014. Euro Surveill 2016; 21.</a></li><li><a class="nounderline abstract_t">Ece G, Erac B, Limoncu MH, et al. Stenotrophomonas maltophilia Pseudo-outbreak at a University Hospital Bronchoscopy Unit in Turkey. West Indian Med J 2014; 63:59.</a></li><li><a class="nounderline abstract_t">Waite TD, Georgiou A, Abrishami M, Beck CR. Pseudo-outbreaks of Stenotrophomonas maltophilia on an intensive care unit in England. J Hosp Infect 2016; 92:392.</a></li><li><a class="nounderline abstract_t">Botana-Rial M, Leiro-Fernández V, Núñez-Delgado M, et al. A Pseudo-Outbreak of Pseudomonas putida and Stenotrophomonas maltophilia in a Bronchoscopy Unit. Respiration 2016; 92:274.</a></li><li><a class="nounderline abstract_t">Murray NH, Goldberg MJ. Traumatic left ventricular aneurysm: report of a case with normal coronary arteries. Int J Cardiol 1989; 24:377.</a></li><li><a class="nounderline abstract_t">Liu B, Tong S. An investigation of Stenotrophomonas maltophilia-positive culture caused by fiberoptic bronchoscope contamination. BMC Infect Dis 2019; 19:1072.</a></li><li><a class="nounderline abstract_t">Gales AC, Jones RN, Forward KR, et al. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis 2001; 32 Suppl 2:S104.</a></li><li><a class="nounderline abstract_t">Micozzi A, Venditti M, Monaco M, et al. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin Infect Dis 2000; 31:705.</a></li><li><a class="nounderline abstract_t">Chen YF, Chung PC, Hsiao CH. Stenotrophomonas maltophilia keratitis and scleritis. Chang Gung Med J 2005; 28:142.</a></li><li><a class="nounderline abstract_t">Penland RL, Wilhelmus KR. Stenotrophomonas maltophilia ocular infections. Arch Ophthalmol 1996; 114:433.</a></li><li><a class="nounderline abstract_t">Ibn Saied W, Merceron S, Schwebel C, et al. Ventilator-associated pneumonia due to Stenotrophomonas maltophilia: Risk factors and outcome. J Infect 2020; 80:279.</a></li><li><a class="nounderline abstract_t">Saugel B, Eschermann K, Hoffmann R, et al. Stenotrophomonas maltophilia in the respiratory tract of medical intensive care unit patients. Eur J Clin Microbiol Infect Dis 2012; 31:1419.</a></li><li><a class="nounderline abstract_t">Araoka H, Fujii T, Izutsu K, et al. Rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in hematologic malignancy. Transpl Infect Dis 2012; 14:355.</a></li><li><a class="nounderline abstract_t">Tada K, Kurosawa S, Hiramoto N, et al. Stenotrophomonas maltophilia infection in hematopoietic SCT recipients: high mortality due to pulmonary hemorrhage. Bone Marrow Transplant 2013; 48:74.</a></li><li><a class="nounderline abstract_t">Salsgiver EL, Fink AK, Knapp EA, et al. Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis. Chest 2016; 149:390.</a></li><li><a class="nounderline abstract_t">Stanojevic S, Ratjen F, Stephens D, et al. Factors influencing the acquisition of Stenotrophomonas maltophilia infection in cystic fibrosis patients. J Cyst Fibros 2013; 12:575.</a></li><li><a class="nounderline abstract_t">Cogen J, Emerson J, Sanders DB, et al. Risk factors for lung function decline in a large cohort of young cystic fibrosis patients. Pediatr Pulmonol 2015; 50:763.</a></li><li><a class="nounderline abstract_t">Boktour M, Hanna H, Ansari S, et al. Central venous catheter and Stenotrophomonas maltophilia bacteremia in cancer patients. Cancer 2006; 106:1967.</a></li><li><a class="nounderline abstract_t">Velázquez-Acosta C, Zarco-Márquez S, Jiménez-Andrade MC, et al. Stenotrophomonas maltophilia bacteremia and pneumonia at a tertiary-care oncology center: a review of 16 years. Support Care Cancer 2018; 26:1953.</a></li><li><a class="nounderline abstract_t">Lai CH, Wong WW, Chin C, et al. Central venous catheter-related Stenotrophomonas maltophilia bacteraemia and associated relapsing bacteraemia in haematology and oncology patients. Clin Microbiol Infect 2006; 12:986.</a></li><li><a class="nounderline abstract_t">Apisarnthanarak A, Mayfield JL, Garison T, et al. Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients: a case-control study. Infect Control Hosp Epidemiol 2003; 24:269.</a></li><li><a class="nounderline abstract_t">Vartivarian SE, Papadakis KA, Anaissie EJ. Stenotrophomonas (Xanthomonas) maltophilia urinary tract infection. A disease that is usually severe and complicated. Arch Intern Med 1996; 156:433.</a></li><li><a class="nounderline abstract_t">Wu AL, Yeh LK, Ma DH, et al. Clinical Characteristics of Stenotrophomonas maltophilia Keratitis. Cornea 2016; 35:795.</a></li><li><a class="nounderline abstract_t">Teo WY, Chan MY, Lam CM, Chong CY. Skin manifestation of Stenotrophomonas maltophilia infection--a case report and review article. Ann Acad Med Singapore 2006; 35:897.</a></li><li><a class="nounderline abstract_t">Son YM, Na SY, Lee HY, et al. Ecthyma Gangrenosum: A Rare Cutaneous Manifestation Caused by Stenotrophomonas maltophilia in a Leukemic Patient. Ann Dermatol 2009; 21:389.</a></li><li><a class="nounderline abstract_t">Pathmanathan A, Waterer GW. Significance of positive Stenotrophomonas maltophilia culture in acute respiratory tract infection. Eur Respir J 2005; 25:911.</a></li><li class="breakAll">US Food and Drug Administration. FDA Drug Safety Communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-increased-risk-death-tygacil-tigecycline-compared-other-antibiotics (Accessed on September 21, 2022).</li><li><a class="nounderline abstract_t">Shah MD, Coe KE, El Boghdadly Z, et al. Efficacy of combination therapy versus monotherapy in the treatment of Stenotrophomonas maltophilia pneumonia. J Antimicrob Chemother 2019; 74:2055.</a></li><li><a class="nounderline abstract_t">Araoka H, Baba M, Okada C, et al. Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patients. Int J Infect Dis 2017; 58:18.</a></li><li><a class="nounderline abstract_t">Biagi M, Vialichka A, Jurkovic M, et al. Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2020; 64.</a></li><li><a class="nounderline abstract_t">Gülmez D, Cakar A, Sener B, et al. Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing. J Infect Chemother 2010; 16:322.</a></li><li><a class="nounderline abstract_t">Liaw SJ, Teng LJ, Hsueh PR, et al. In vitro activities of antimicrobial combinations against clinical isolates of Stenotrophomonas maltophilia. J Formos Med Assoc 2002; 101:495.</a></li><li><a class="nounderline abstract_t">Poulos CD, Matsumura SO, Willey BM, et al. In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia. Antimicrob Agents Chemother 1995; 39:2220.</a></li><li><a class="nounderline abstract_t">Zelenitsky SA, Iacovides H, Ariano RE, Harding GK. Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 2005; 51:39.</a></li><li><a class="nounderline abstract_t">Yu VL, Felegie TP, Yee RB, et al. Synergistic interaction in vitro with use of three antibiotics simultaneously against Pseudomonas maltophilia. J Infect Dis 1980; 142:602.</a></li><li><a class="nounderline abstract_t">Wei C, Ni W, Cai X, et al. Evaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill Experiments. PLoS One 2016; 11:e0152132.</a></li><li><a class="nounderline abstract_t">Yilmaz M, Celik AF, Mert A. Successfully treated nosocomial Stenotrophomonas maltophilia bacteremia following desensitization to trimethoprim-sulfamethoxazole. J Infect Chemother 2007; 13:122.</a></li><li><a class="nounderline abstract_t">Biagi M, Lamm D, Meyer K, et al. Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2020; 64.</a></li><li><a class="nounderline abstract_t">Lin Q, Zou H, Chen X, et al. Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro. BMC Microbiol 2021; 21:60.</a></li><li><a class="nounderline abstract_t">Cowart MC, Ferguson CL. Optimization of Aztreonam in Combination With Ceftazidime/Avibactam in a Cystic Fibrosis Patient With Chronic Stenotrophomonas maltophilia Pneumonia Using Therapeutic Drug Monitoring: A Case Study. Ther Drug Monit 2021; 43:146.</a></li><li><a class="nounderline abstract_t">Diarra A, Pascal L, Carpentier B, et al. Successful use of avibactam and aztreonam combination for a multiresistant Stenotrophomonas maltophilia bloodstream infection in a patient with idiopathic medullary aplasia. Infect Dis Now 2021; 51:637.</a></li><li><a class="nounderline abstract_t">Mojica MF, Ouellette CP, Leber A, et al. Successful Treatment of Bloodstream Infection Due to Metallo-β-Lactamase-Producing Stenotrophomonas maltophilia in a Renal Transplant Patient. Antimicrob Agents Chemother 2016; 60:5130.</a></li><li><a class="nounderline abstract_t">Wang YL, Scipione MR, Dubrovskaya Y, Papadopoulos J. Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. Antimicrob Agents Chemother 2014; 58:176.</a></li><li><a class="nounderline abstract_t">Tekçe YT, Erbay A, Cabadak H, Sen S. Tigecycline as a therapeutic option in Stenotrophomonas maltophilia infections. J Chemother 2012; 24:150.</a></li><li><a class="nounderline abstract_t">Hand E, Davis H, Kim T, Duhon B. Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. J Antimicrob Chemother 2016; 71:1071.</a></li><li><a class="nounderline abstract_t">Nys C, Cherabuddi K, Venugopalan V, Klinker KP. Clinical and Microbiologic Outcomes in Patients with Monomicrobial Stenotrophomonas maltophilia Infections. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Ko JH, Kang CI, Cornejo-Juárez P, et al. Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis. Clin Microbiol Infect 2019; 25:546.</a></li><li><a class="nounderline abstract_t">Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. Int J Antimicrob Agents 2014; 43:328.</a></li><li><a class="nounderline abstract_t">Chang YT, Lin CY, Chen YH, Hsueh PR. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. Front Microbiol 2015; 6:893.</a></li><li><a class="nounderline abstract_t">Cho SY, Lee DG, Choi SM, et al. Stenotrophomonas maltophilia bloodstream infection in patients with hematologic malignancies: a retrospective study and in vitro activities of antimicrobial combinations. BMC Infect Dis 2015; 15:69.</a></li><li><a class="nounderline abstract_t">Cai B, Tillotson G, Benjumea D, et al. The Burden of Bloodstream Infections due to Stenotrophomonas Maltophilia in the United States: A Large, Retrospective Database Study. Open Forum Infect Dis 2020; 7:ofaa141.</a></li><li><a class="nounderline abstract_t">Tsiodras S, Pittet D, Carmeli Y, et al. Clinical implications of stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals. Scand J Infect Dis 2000; 32:651.</a></li><li><a class="nounderline abstract_t">Wang CH, Lin JC, Lin HA, et al. Comparisons between patients with trimethoprim-sulfamethoxazole-susceptible and trimethoprim-sulfamethoxazole-resistant Stenotrophomonas maltophilia monomicrobial bacteremia: A 10-year retrospective study. J Microbiol Immunol Infect 2016; 49:378.</a></li><li><a class="nounderline abstract_t">Jacobson S, Junco Noa L, Wallace MR, Bowman MC. Clinical outcomes using minocycline for Stenotrophomonas maltophilia infections. J Antimicrob Chemother 2016; 71:3620.</a></li><li><a class="nounderline abstract_t">Shortridge D, Arends SJR, Streit JM, Castanheira M. Minocycline Activity against Unusual Clinically Significant Gram-Negative Pathogens. Antimicrob Agents Chemother 2021; 65:e0126421.</a></li><li><a class="nounderline abstract_t">Biagi M, Tan X, Wu T, et al. Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole. J Clin Microbiol 2020; 58.</a></li><li><a class="nounderline abstract_t">Cho SY, Kang CI, Kim J, et al. Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia? Antimicrob Agents Chemother 2014; 58:581.</a></li><li><a class="nounderline abstract_t">Sarzynski SH, Warner S, Sun J, et al. Trimethoprim-Sulfamethoxazole Versus Levofloxacin for Stenotrophomonas maltophilia Infections: A Retrospective Comparative Effectiveness Study of Electronic Health Records from 154 US Hospitals. Open Forum Infect Dis 2022; 9:ofab644.</a></li><li><a class="nounderline abstract_t">Ba BB, Feghali H, Arpin C, et al. Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. Antimicrob Agents Chemother 2004; 48:946.</a></li><li><a class="nounderline abstract_t">Garrison MW, Anderson DE, Campbell DM, et al. Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model. Antimicrob Agents Chemother 1996; 40:2859.</a></li><li><a class="nounderline abstract_t">Galles AC, Jones RN, Sader HS. Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results? J Chemother 2008; 20:38.</a></li><li><a class="nounderline abstract_t">Delgado-Valverde M, Conejo MDC, Serrano L, et al. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia. J Antimicrob Chemother 2020; 75:1840.</a></li><li><a class="nounderline abstract_t">Bassetti M, Ariyasu M, Binkowitz B, et al. Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens - The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study. Infect Drug Resist 2019; 12:3607.</a></li><li class="breakAll">US Food and Drug Administration. Antimicrobial Drugs Advisory Committee. Cefiderocol briefing document, NDA #209445, 2019. https://www.fda.gov/media/131705/download (Accessed on August 10, 2020).</li><li><a class="nounderline abstract_t">Mojica MF, Papp-Wallace KM, Taracila MA, et al. Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam. Antimicrob Agents Chemother 2017; 61.</a></li><li><a class="nounderline abstract_t">Sader HS, Duncan LR, Arends SJR, et al. Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide. Antimicrob Agents Chemother 2020; 64.</a></li><li><a class="nounderline abstract_t">Emeraud C, Escaut L, Boucly A, et al. Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria. Antimicrob Agents Chemother 2019; 63.</a></li><li class="breakAll">CLSI M100-ED32: 2022 Performance standards for antimicrobial susceptibility testing, 32nd edition. http://em100.edaptivedocs.net/GetDoc.aspx?doc=CLSI%20M100%20ED32:2022&amp;sbssok=CLSI%20M100%20ED32:2022%20APPENDIX%20B&amp;format=HTML&amp;hl=stenotrophomonas (Accessed on August 17, 2022).</li><li><a class="nounderline abstract_t">Khan A, Pettaway C, Dien Bard J, et al. Evaluation of the Performance of Manual Antimicrobial Susceptibility Testing Methods and Disk Breakpoints for Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2023; 95.</a></li><li><a class="nounderline abstract_t">Khan A, Arias CA, Abbott A, et al. Evaluation of the Vitek 2, Phoenix, and MicroScan for Antimicrobial Susceptibility Testing of Stenotrophomonas maltophilia. J Clin Microbiol 2021; 59:e0065421.</a></li><li><a class="nounderline abstract_t">Satlin MJ, Lewis JS, Weinstein MP, et al. Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing Position Statements on Polymyxin B and Colistin Clinical Breakpoints. Clin Infect Dis 2020; 71:e523.</a></li><li><a class="nounderline abstract_t">Martínez-Servat S, Yero D, Huedo P, et al. Heterogeneous Colistin-Resistance Phenotypes Coexisting in Stenotrophomonas maltophilia Isolates Influence Colistin Susceptibility Testing. Front Microbiol 2018; 9:2871.</a></li><li><a class="nounderline abstract_t">Moskowitz SM, Garber E, Chen Y, et al. Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia. J Antimicrob Chemother 2010; 65:1416.</a></li><li><a class="nounderline abstract_t">Sader HS, Jones RN. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int J Antimicrob Agents 2005; 25:95.</a></li><li><a class="nounderline abstract_t">Senol E, DesJardin J, Stark PC, et al. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis 2002; 34:1653.</a></li><li><a class="nounderline abstract_t">Wang WS, Liu CP, Lee CM, Huang FY. Stenotrophomonas maltophilia bacteremia in adults: four years' experience in a medical center in northern Taiwan. J Microbiol Immunol Infect 2004; 37:359.</a></li><li><a class="nounderline abstract_t">Hashimoto T, Komiya K, Fujita N, et al. Risk factors for 30-day mortality among patients with Stenotrophomonas maltophilia bacteraemia. Infect Dis (Lond) 2020; 52:440.</a></li><li><a class="nounderline abstract_t">Barchitta M, Cipresso R, Giaquinta L, et al. Acquisition and spread of Acinetobacter baumannii and Stenotrophomonas maltophilia in intensive care patients. Int J Hyg Environ Health 2009; 212:330.</a></li></ol></div><div id="topicVersionRevision">Topic 13961 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18483755" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Factors associated with mortality in patients with bloodstream infection and pneumonia due to Stenotrophomonas maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19037515" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Independent predictors for mortality in patients with positive Stenotrophomonas maltophilia cultures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15599467" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9457429" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12789473" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Stenotrophomonas (Xanthomonas) maltophilia as an emerging opportunistic pathogen in association with HIV infection: a 10-year surveillance study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12789473" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Stenotrophomonas (Xanthomonas) maltophilia as an emerging opportunistic pathogen in association with HIV infection: a 10-year surveillance study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19393961" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Stenotrophomonas maltophilia: an emerging opportunist human pathogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419807" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9174542" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Fatal pulmonary hemorrhage in patients with acute leukemia and fulminant pneumonia caused by Stenotrophomonas maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8649636" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Relapsing pyrogenic reactions due to Xanthomonas maltophilia in a dialysis patient with a long-term central venous catheter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8051648" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Meningitis due to Xanthomonas maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12536991" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Successful treatment of multi-resistant Stenotrophomonas maltophilia meningitis with ciprofloxacin in a pre-term infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8645796" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Stenotrophomonas maltophilia: an unusual cause of biliary sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8838214" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Septic prepatellar bursitis caused by Stenotrophomonas (Xanthomonas) maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17894750" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cutaneous infections with Stenotrophomonas maltophilia in patients using immunosuppressive medication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4641655" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Infrequently encountered Pseudomonas species causing infection in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2267495" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17334747" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Antimicrobial therapy for Stenotrophomonas maltophilia infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5766111" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pseudomonas maltophilia infections in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2313082" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19895214" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3537006" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pseudomonas maltophilia exoenzyme activity as correlate in pathogenesis of ecthyma gangrenosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8808938" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Adhesion of the positively charged bacterium Stenotrophomonas (Xanthomonas) maltophilia 70401 to glass and Teflon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12925132" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Fimbriae and adherence of Stenotrophomonas maltophilia to epithelial cells and to abiotic surfaces.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14693533" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Biofilm formation by Stenotrophomonas maltophilia: modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12364374" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12194767" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Characterization of flagella produced by clinical strains of Stenotrophomonas maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17220304" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11158734" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Plasmid location and molecular heterogeneity of the L1 and L2 beta-lactamase genes of Stenotrophomonas maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9559809" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Overexpression, purification, and characterization of the cloned metallo-beta-lactamase L1 from Stenotrophomonas maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6609682" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Purification and properties of an inducible cephalosporinase from Pseudomonas maltophilia GN12873.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9210666" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Sequence analysis and enzyme kinetics of the L2 serine beta-lactamase from Stenotrophomonas maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31266860" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Population Structure, Molecular Epidemiology, andβ-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31266860" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Population Structure, Molecular Epidemiology, andβ-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7560984" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9710677" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10508008" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Characterization of the chromosomal aac(6')-Iz gene of Stenotrophomonas maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12654758" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Role of the acetyltransferase AAC(6')-Iz modifying enzyme in aminoglycoside resistance in Stenotrophomonas maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12022261" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Outer membranes and efflux: the path to multidrug resistance in Gram-negative bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18190323" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18662945" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4044874" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effect of temperature on antimicrobial susceptibilities of Pseudomonas maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8522461" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Growth temperature-dependent variation of cell envelope lipids and antibiotic susceptibility in Stenotrophomonas (Xanthomonas) maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8722532" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Temperature-dependent aminoglycoside resistance in Stenotrophomonas (Xanthomonas) maltophilia; alterations in protein and lipopolysaccharide with growth temperature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9044023" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effect of temperature on aminoglycoside binding sites in Stenotrophomonas maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11036026" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11353642" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Expression of multidrug efflux pump SmeDEF by clinical isolates of Stenotrophomonas maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11581236" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10858330" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Stenotrophomonas maltophilia D457R contains a cluster of genes from gram-positive bacteria involved in antibiotic and heavy metal resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11997719" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clinical epidemiology of Stenotrophomonas maltophilia colonization and infection: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16978420" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15460530" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Stenotrophomonas maltophilia as a nosocomial pathogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7840563" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Susceptibilities of 123 strains of Xanthomonas maltophilia to eight beta-lactams (including beta-lactam-beta-lactamase inhibitor combinations) and ciprofloxacin tested by five methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12435710" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : In vitro killing effect of moxifloxacin on clinical isolates of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12435710" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : In vitro killing effect of moxifloxacin on clinical isolates of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20368399" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20368399" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3487553" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8852971" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18621440" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Risk factors associated with mortality of infections caused by Stenotrophomonas maltophilia: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8036472" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Xanthomonas maltophilia bacteremia in immunocompromised hematological patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9195070" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Comparison of treatment with imipenem vs. ceftazidime as a predisposing factor for nosocomial acquisition of Stenotrophomonas maltophilia: a historical cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19224257" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Community-acquired Stenotrophomonas maltophilia infections: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24148363" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Outbreak of Stenotrophomonas maltophilia on an intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10466556" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Two consecutive outbreaks of Stenotrophomonas maltophilia (Xanthomonas maltophilia) in an intensive-care unit defined by restriction fragment-length polymorphism typing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9949380" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Faucet aerators: A source of patient colonization with Stenotrophomonas maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10619754" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Outbreak of Stenotrophomonas maltophilia bacteremia in allogenic bone marrow transplant patients: role of severe neutropenia and mucositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12018671" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Fulminant Stenotrophomonas maltophilia soft tissue infection in immunocompromised patients: an outbreak transmitted via tap water.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Outbreak of Stenotrophomonas maltophilia bloodstream infections in an outpatient dialysis center</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9692603" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Nosocomial outbreak of colonization and infection with Stenotrophomonas maltophilia in preterm infants associated with contaminated tap water.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Stenotrophomonas maltophilia outbreak in neonatal intensive care unit and outbreak management</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22232370" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : An outbreak of trimethoprim/sulfamethoxazole-resistant Stenotrophomonas maltophilia meningitis associated with neuroendoscopy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27458712" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Outbreak of pulmonary Pseudomonas aeruginosa and Stenotrophomonas maltophilia infections related to contaminated bronchoscope suction valves, Lyon, France, 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25303196" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Stenotrophomonas maltophilia Pseudo-outbreak at a University Hospital Bronchoscopy Unit in Turkey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26876747" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Pseudo-outbreaks of Stenotrophomonas maltophilia on an intensive care unit in England.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27627819" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A Pseudo-Outbreak of Pseudomonas putida and Stenotrophomonas maltophilia in a Bronchoscopy Unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2767819" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Traumatic left ventricular aneurysm: report of a case with normal coronary arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31864284" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : An investigation of Stenotrophomonas maltophilia-positive culture caused by fiberoptic bronchoscope contamination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11320451" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11017819" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15945320" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Stenotrophomonas maltophilia keratitis and scleritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8602781" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Stenotrophomonas maltophilia ocular infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31682878" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Ventilator-associated pneumonia due to Stenotrophomonas maltophilia: Risk factors and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22057419" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Stenotrophomonas maltophilia in the respiratory tract of medical intensive care unit patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22283869" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in hematologic malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22635245" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Stenotrophomonas maltophilia infection in hematopoietic SCT recipients: high mortality due to pulmonary hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26203598" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23757360" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Factors influencing the acquisition of Stenotrophomonas maltophilia infection in cystic fibrosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26061914" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Risk factors for lung function decline in a large cohort of young cystic fibrosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16565968" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Central venous catheter and Stenotrophomonas maltophilia bacteremia in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29307014" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Stenotrophomonas maltophilia bacteremia and pneumonia at a tertiary-care oncology center: a review of 16 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16961635" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Central venous catheter-related Stenotrophomonas maltophilia bacteraemia and associated relapsing bacteraemia in haematology and oncology patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12725356" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8607729" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Stenotrophomonas (Xanthomonas) maltophilia urinary tract infection. A disease that is usually severe and complicated.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27100655" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Clinical Characteristics of Stenotrophomonas maltophilia Keratitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17219003" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Skin manifestation of Stenotrophomonas maltophilia infection--a case report and review article.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20523829" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Ecthyma Gangrenosum: A Rare Cutaneous Manifestation Caused by Stenotrophomonas maltophilia in a Leukemic Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15863651" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Significance of positive Stenotrophomonas maltophilia culture in acute respiratory tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15863651" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Significance of positive Stenotrophomonas maltophilia culture in acute respiratory tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30945726" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Efficacy of combination therapy versus monotherapy in the treatment of Stenotrophomonas maltophilia pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28257816" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32571820" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant Stenotrophomonas maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20449623" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12353342" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : In vitro activities of antimicrobial combinations against clinical isolates of Stenotrophomonas maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8619571" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15629227" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7441019" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Synergistic interaction in vitro with use of three antibiotics simultaneously against Pseudomonas maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26999818" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Evaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill Experiments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17458682" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Successfully treated nosocomial Stenotrophomonas maltophilia bacteremia following desensitization to trimethoprim-sulfamethoxazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32928733" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33618662" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33315762" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Optimization of Aztreonam in Combination With Ceftazidime/Avibactam in a Cystic Fibrosis Patient With Chronic Stenotrophomonas maltophilia Pneumonia Using Therapeutic Drug Monitoring: A Case Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33870895" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Successful use of avibactam and aztreonam combination for a multiresistant Stenotrophomonas maltophilia bloodstream infection in a patient with idiopathic medullary aplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27551008" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Successful Treatment of Bloodstream Infection Due to Metallo-β-Lactamase-Producing Stenotrophomonas maltophilia in a Renal Transplant Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24145530" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22759759" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Tigecycline as a therapeutic option in Stenotrophomonas maltophilia infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26801080" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31427300" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Clinical and Microbiologic Outcomes in Patients with Monomicrobial Stenotrophomonas maltophilia Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30448331" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24630306" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26388847" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25887489" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Stenotrophomonas maltophilia bloodstream infection in patients with hematologic malignancies: a retrospective study and in vitro activities of antimicrobial combinations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32462047" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : The Burden of Bloodstream Infections due to Stenotrophomonas Maltophilia in the United States: A Large, Retrospective Database Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11200376" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Clinical implications of stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25081988" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Comparisons between patients with trimethoprim-sulfamethoxazole-susceptible and trimethoprim-sulfamethoxazole-resistant Stenotrophomonas maltophilia monomicrobial bacteremia: A 10-year retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27516472" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Clinical outcomes using minocycline for Stenotrophomonas maltophilia infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34491809" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Minocycline Activity against Unusual Clinically Significant Gram-Negative Pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31748318" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24126583" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35097154" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Trimethoprim-Sulfamethoxazole Versus Levofloxacin for Stenotrophomonas maltophilia Infections: A Retrospective Comparative Effectiveness Study of Electronic Health Records from 154 US Hospitals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14982788" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9124855" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18343741" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32277821" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31819544" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens - The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31819544" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens - The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28784669" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32900683" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30858212" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30858212" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33558287" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Evaluation of the Performance of Manual Antimicrobial Susceptibility Testing Methods and Disk Breakpoints for Stenotrophomonas maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34011524" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Evaluation of the Vitek 2, Phoenix, and MicroScan for Antimicrobial Susceptibility Testing of Stenotrophomonas maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32052041" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing Position Statements on Polymyxin B and Colistin Clinical Breakpoints.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30524420" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Heterogeneous Colistin-Resistance Phenotypes Coexisting in Stenotrophomonas maltophilia Isolates Influence Colistin Susceptibility Testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20430789" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15664479" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12032905" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Attributable mortality of Stenotrophomonas maltophilia bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15599468" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Stenotrophomonas maltophilia bacteremia in adults: four years' experience in a medical center in northern Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32122208" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Risk factors for 30-day mortality among patients with Stenotrophomonas maltophilia bacteraemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18771951" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Acquisition and spread of Acinetobacter baumannii and Stenotrophomonas maltophilia in intensive care patients.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
